CIK 0002096997 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Kailera Therapeutics, Inc.
Sign in to watch- Ticker
- KLRA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 508-440-9475
- Business address
- 180 THIRD AVENUE, 4TH FLOOR, WALTHAM, MA, 02451
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Option exercise CEO & President acquired 38,094 shares (option exercise)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- SCHEDULE 13D Stake Beneficial Ownership Report
- SCHEDULE 13D Stake Beneficial Ownership Report
- 4 Open-market buy 10% owner bought 500,000 shares at $16.00 ($8,000,000)
- 4 Conversion 10% owner acquired 11,511,852 shares (conversion)
- 4 Open-market buy 10% owner bought 8,398,438 shares at $16.00 ($134,375,008)
- 4 Open-market buy Director bought 1,562,500 shares at $16.00 ($25,000,000)
Page 1 of 4 · 64 filings